In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Ironwood Pharmaceuticals,
Inc. (NASDAQ:IRWD), State Street Corporation (NYSE:STT), CMS Energy
Corporation (NYSE:CMS), Virtus Investment Partners, Inc.
(NASDAQ:VRTS), Capstone Turbine Corporation (NASDAQ:CPST), and
UROGEN PHARMA (NASDAQ:URGN), including updated fundamental
summaries, consolidated fiscal reporting, and fully-qualified
certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
IRWD DOWNLOAD:
http://Capital-Review.com/register/?so=IRWD STT DOWNLOAD:
http://Capital-Review.com/register/?so=STT CMS DOWNLOAD:
http://Capital-Review.com/register/?so=CMS VRTS DOWNLOAD:
http://Capital-Review.com/register/?so=VRTS CPST DOWNLOAD:
http://Capital-Review.com/register/?so=CPST URGN DOWNLOAD:
http://Capital-Review.com/register/?so=URGN
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine Ironwood
Pharmaceuticals, Inc. (NASDAQ:IRWD), State Street Corporation
(NYSE:STT), CMS Energy Corporation (NYSE:CMS), Virtus Investment
Partners, Inc. (NASDAQ:VRTS), Capstone Turbine Corporation
(NASDAQ:CPST), and UROGEN PHARMA (NASDAQ:URGN) on a fundamental
level and outlines the overall demand for their products and
services in addition to an in-depth review of the business
strategy, management discussion, and overall direction going
forward. Several excerpts from the recently released reports are
available to today's readers below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. Percentage
calculations are performed after rounding. All amounts in millions
(MM), except per share amounts.
-----------------------------------------
IRONWOOD PHARMACEUTICALS, INC. (IRWD) REPORT
OVERVIEW
Ironwood Pharmaceuticals' Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Ironwood Pharmaceuticals reported revenue
of $130.69MM vs $94.21MM (up 38.73%) and analysts estimated basic
earnings per share -$0.10 vs $0.10. For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Ironwood
Pharmaceuticals reported revenue of $346.64MM vs $298.28MM (up
16.21%) and analysts estimated basic earnings per share -$1.85 vs
-$0.78. Analysts expect earnings to be released on May 7th, 2019.
The report will be for the fiscal period ending March 31st, 2019.
The reported EPS for the same quarter last year was -$0.27. The
estimated EPS forecast for the next fiscal year is $0.57 and is
expected to report on February 12th, 2020.
To read the full Ironwood Pharmaceuticals, Inc. (IRWD) report,
download it here:
http://Capital-Review.com/register/?so=IRWD
-----------------------------------------
STATE STREET CORPORATION (STT) REPORT
OVERVIEW
State Street's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, State Street reported interest income of
$982.00MM vs $797.00MM (up 23.21%) and analysts estimated basic
earnings per share $1.03 vs $0.90 (up 14.44%). For the twelve
months ended December 31st, 2018 vs December 31st, 2017, State
Street reported interest income of $3,662.00MM vs $2,908.00MM (up
25.93%) and analysts estimated basic earnings per share $6.48 vs
$5.32 (up 21.80%). Analysts expect earnings to be released on April
23rd, 2019. The report will be for the fiscal period ending March
31st, 2019. Reported EPS for the same quarter last year was $1.62.
The estimated EPS forecast for the next fiscal year is $7.51 and is
expected to report on January 17th, 2020.
To read the full State Street Corporation (STT) report, download
it here:
http://Capital-Review.com/register/?so=STT
-----------------------------------------
CMS ENERGY CORPORATION (CMS) REPORT
OVERVIEW
CMS Energy's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, CMS Energy reported revenue of $1,829.00MM
vs $1,778.00MM (up 2.87%) and analysts estimated basic earnings per
share $0.38 vs -$0.01. For the twelve months ended December 31st,
2018 vs December 31st, 2017, CMS Energy reported revenue of
$6,873.00MM vs $6,583.00MM (up 4.41%) and analysts estimated basic
earnings per share $2.33 vs $1.64 (up 42.07%). Analysts expect
earnings to be released on April 25th, 2019. The report will be for
the fiscal period ending March 31st, 2019. Reported EPS for the
same quarter last year was $0.86. The estimated EPS forecast for
the next fiscal year is $2.68 and is expected to report on January
30th, 2020.
To read the full CMS Energy Corporation (CMS) report, download
it here:
http://Capital-Review.com/register/?so=CMS
-----------------------------------------
VIRTUS INVESTMENT PARTNERS, INC. (VRTS) REPORT
OVERVIEW
Virtus Investment Partners' Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Virtus Investment Partners reported revenue
of $138.07MM vs $128.02MM (up 7.84%) and basic earnings per share
$0.04 vs $0.44 (down 90.91%). For the twelve months ended December
31st, 2018 vs December 31st, 2017, Virtus Investment Partners
reported revenue of $552.24MM vs $425.61MM (up 29.75%) and analysts
estimated basic earnings per share $9.37 vs $4.09 (up 129.10%).
Analysts expect earnings to be released on April 26th, 2019. The
report will be for the fiscal period ending March 31st, 2019. The
reported EPS for the same quarter last year was $2.59. The
estimated EPS forecast for the next fiscal year is $11.67 and is
expected to report on February 7th, 2020.
To read the full Virtus Investment Partners, Inc. (VRTS) report,
download it here:
http://Capital-Review.com/register/?so=VRTS
-----------------------------------------
CAPSTONE TURBINE CORPORATION (CPST) REPORT
OVERVIEW
Capstone Turbine's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Capstone Turbine reported revenue of
$18.03MM vs $22.76MM (down 20.79%) and analysts estimated basic
earnings per share -$0.05 vs -$0.01. For the twelve months ended
March 31st, 2018 vs March 31st, 2017, Capstone Turbine reported
revenue of $82.84MM vs $77.17MM (up 7.34%) and analysts estimated
basic earnings per share -$0.20 vs -$0.79. Analysts expect earnings
to be released on June 6th, 2019. The report will be for the fiscal
period ending March 31st, 2019. The reported EPS for the same
quarter last year was -$0.02. The estimated EPS forecast for the
next fiscal year is -$0.05 and is expected to report on June 6th,
2019.
To read the full Capstone Turbine Corporation (CPST) report,
download it here:
http://Capital-Review.com/register/?so=CPST
-----------------------------------------
UROGEN PHARMA (URGN) REPORT OVERVIEW
UROGEN PHARMA's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, UROGEN PHARMA reported revenue of $0.00MM
vs $0.33MM and analysts estimated basic earnings per share -$1.50
vs $0.32. For the twelve months ended December 31st, 2018 vs
December 31st, 2017, UROGEN PHARMA reported revenue of $1.13MM vs
$8.16MM (down 86.17%) and analysts estimated basic earnings per
share -$4.80 vs -$2.14. Analysts expect earnings to be released on
May 21st, 2019. The report will be for the fiscal period ending
March 31st, 2019. The reported EPS for the same quarter last year
was -$0.88. The estimated EPS forecast for the next fiscal year is
-$3.66 and is expected to report on February 27th, 2020.
To read the full UROGEN PHARMA (URGN) report, download it here:
http://Capital-Review.com/register/?so=URGN
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Morena Zambada, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
Capstone Turbine (NASDAQ:CPST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Capstone Turbine (NASDAQ:CPST)
Historical Stock Chart
From Sep 2023 to Sep 2024